Edition:
India

Ignyta Inc (RXDX.OQ)

RXDX.OQ on NASDAQ Stock Exchange Capital Market

15.25USD
15 Dec 2017
Change (% chg)

$-0.30 (-1.93%)
Prev Close
$15.55
Open
$15.60
Day's High
$15.80
Day's Low
$15.07
Volume
1,488,461
Avg. Vol
257,972
52-wk High
$18.25
52-wk Low
$4.65

Chart for

About

Ignyta, Inc. is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company's pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.... (more)

Overall

Beta: -1.02
Market Cap(Mil.): $742.55
Shares Outstanding(Mil.): 56.25
Dividend: --
Yield (%): --

Financials

BRIEF-Ignyta announces new data highlighting immune modulation of RXDX-106 at the society for immunotherapy of cancer meeting

* Ignyta announces new data highlighting immune modulation of RXDX-106 at the society for immunotherapy of cancer (sitc) meeting Source text for Eikon: Further company coverage:

08 Nov 2017

BRIEF-Ignyta Inc files for potential mixed shelf offering; size not disclosed

* Ignyta Inc files for potential mixed shelf offering; size not disclosed - SEC filing‍​ Source text: (http://bit.ly/2gt6zxh) Further company coverage:

19 Oct 2017

BRIEF-Ignyta receives EMA PRIME designation for entrectinib in NTRK fusion-positive solid tumors

* Ignyta receives European Medicines Agency prime designation for entrectinib in NTRK fusion-positive solid tumors Source text for Eikon: Further company coverage:

17 Oct 2017

BRIEF-Ignyta Inc - ‍announced new preclinical data for RXDX-106​

* Ignyta Inc - ‍in study, researchers demonstrated immune-mediated, single-agent anti-tumor activity of RXDX-106 in multiple tumor models​ Source text for Eikon: Further company coverage:

03 Oct 2017

BRIEF-Ignyta Q2 loss per share $0.56

* Ignyta announces second quarter 2017 company highlights and financial results

09 Aug 2017

BRIEF-Ignyta receives FDA orphan drug designation for entrectinib

* Ignyta receives FDA orphan drug designation for entrectinib for treatment of NTRK fusion-positive solid tumors

10 Jul 2017

Earnings vs. Estimates